Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
- 6 February 2024
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (2) , e14249
Abstract
Background: Neuraminidase inhibitors, including oseltamivir, are the treatment standard for influenza. Baloxavir, a novel antiviral, demonstrated comparable outcomes to oseltamivir in outpatients with influenza. Baloxavir was equally effective as oseltamivir in a retrospective study of hospitalized patients with influenza at our institution. However, the efficacy of baloxavir in immunocompromised patients is unclear.Methods: We conducted a retrospective cohort study of immunocompromised adult patients hospitalized with influenza A who received baloxavir from January 2019 to April 2019 or oseltamivir from January 2018 to April 2018. Demographic and clinical outcomes were assessed. Primary outcomes were time from antiviral initiation to resolution of hypoxia and fever. Secondary outcomes were length of stay (LOS), intensive care unit (ICU) care, ICU LOS, and 30‐day mortality.Results: Of 95 total patients, 52 received baloxavir and 43 received oseltamivir. Other than younger age (57.5 vs. 65; p = .035) and longer duration between vaccination and symptom onset (114 vs. 86 days; p = .001) in the baloxavir group, baseline characteristics did not differ. H1 was the predominant subtype in the baloxavir group (65.3%) versus H3 in the oseltamivir group (85.7%). When comparing baloxavir to oseltamivir, there was no significant difference in median time from antiviral initiation to resolution of hypoxia (59.9 vs. 42.5 h) and to resolution of fever (21.6 vs. 26.6 h). There were no differences in secondary outcomes.Conclusion: Baloxavir was not associated with longer time to resolution of hypoxia or fever in comparison to oseltamivir. Results must be taken in context of variations in seasonal influenza subtype and resistance rates. imageKeywords
This publication has 20 references indexed in Scilit:
- RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of PracticeClinical Transplantation, 2019
- Baloxavir Marboxil for Uncomplicated Influenza in Adults and AdolescentsNew England Journal of Medicine, 2018
- A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant RecipientsClinical Infectious Diseases, 2018
- Seasonal influenza vaccine in immunocompromised personsHuman Vaccines & Immunotherapeutics, 2018
- Drug resistance in influenza A virus: the epidemiology and managementInfection and Drug Resistance, 2017
- Influenza prevention and treatment in transplant recipients and immunocompromised hostsInfluenza and Other Respiratory Viruses, 2013
- Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trialBMJ, 2013
- Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1Journal of Clinical Virology, 2011
- Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposureTransplant Infectious Disease, 2010
- A Comparison of the Effectiveness of Oseltamivir for the Treatment of Influenza A and Influenza B: A Japanese Multicenter Study of the 2003-2004 and 2004-2005 Influenza SeasonsClinical Infectious Diseases, 2006